In this view, in 2014, Domschke et al. investigated the correlation between SLC6A4 methylation level and impaired response to antidepressant drugs after six weeks of treatment in patients with major depressive disorder (MDD), suggesting that individuals’ methylation profile may contribute to improve a personalized therapy [76,77]. Here, SLC6A4 is linked to major depressive disorder.